Literature DB >> 9257082

Tacalcitol.

D C Peters1, J A Balfour.   

Abstract

Tacalcitol is a vitamin D3 analogue which is available in Japan as a 2 micrograms/g ointment for twice daily application and in Western markets as a 4 micrograms/g ointment for once daily application. Tacalcitol inhibits proliferation, and induces the differentiation, of keratinocytes. In addition, it appears to modulate inflammatory and immunological mediators in the skin which may be involved in the aetiology of psoriasis. No significant systemic drug absorption occurs after application of tacalcitol to the skin. Results of clinical trials indicate that topical tacalcitol is effective in the management of stable plaque psoriasis (and possibly pustular forms of the disease), and has a similar efficacy to topical betamethasone valerate in this setting. Application of tacalcitol ointment 4 micrograms/g once daily for up to 8 weeks did not cause hypercalcaemia or hypercalciuria. Mild local skin irritation has been reported in a variable proportion of patients (< or = 12%).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257082     DOI: 10.2165/00003495-199754020-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

Review 1.  Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists.

Authors: 
Journal:  BMJ       Date:  1991-10-05

2.  Effect of 1,24-dihydroxyvitamin D3 on proliferation stimulated by epidermal growth factor in cultured mouse epidermal keratinocytes.

Authors:  T Ohta; H Mimura; M Kiyoki
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

3.  Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1 alpha,24-dihydroxycholecalciferol.

Authors:  T Kato; M Rokugo; T Terui; H Tagami
Journal:  Br J Dermatol       Date:  1986-10       Impact factor: 9.302

Review 4.  Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms.

Authors:  P C van de Kerkhof
Journal:  Br J Dermatol       Date:  1995-05       Impact factor: 9.302

5.  Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes.

Authors:  K Matsumoto; K Hashimoto; M Kiyoki; M Yamamoto; K Yoshikawa
Journal:  J Dermatol       Date:  1990-02       Impact factor: 4.005

6.  Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions.

Authors:  I Katayama; K Minatohara; H Yokozeki; K Nishioka
Journal:  Int Arch Allergy Immunol       Date:  1996-09       Impact factor: 2.749

7.  1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity.

Authors:  T Matsunaga; M Yamamoto; H Mimura; T Ohta; M Kiyoki; T Ohba; T Naruchi; J Hosoi; T Kuroki
Journal:  J Dermatol       Date:  1990-03       Impact factor: 4.005

8.  Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety.

Authors:  P C Van de Kerkhof; T Werfel; U F Haustein; T Luger; B M Czarnetzki; R Niemann; V Plänitz-Stenzel
Journal:  Br J Dermatol       Date:  1996-11       Impact factor: 9.302

9.  The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study.

Authors:  M J Gerritsen; J B Boezeman; I M van Vlijmen-Willems; P C Van de Kerkhof
Journal:  Br J Dermatol       Date:  1994-07       Impact factor: 9.302

10.  Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation.

Authors:  C P Glade; P E van Erp; C A van Hooijdonk; M E Elbers; P C van de Kerkhof
Journal:  Acta Derm Venereol       Date:  1995-09       Impact factor: 4.437

View more
  1 in total

1.  Relation Between Crystal Structures of Precursors and Final Products: Example of Vitamin D Intermediates.

Authors:  Monika Wanat; Maura Malinska; Andrzej Kutner; Krzysztof Woźniak
Journal:  Molecules       Date:  2020-04-14       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.